StreetAlpha.app
Home › Stocks › AZN

Astrazeneca PLC (AZN)

Healthcare
$174.35
▼ −0.60%
LAST CLOSE · NOV 20

AstraZeneca is a pharmaceutical company that develops and sells prescription medicines for cancer, heart, lung and other diseases. It last closed at $174.35 on Nov 20, down 0.60% on the day. Over the last 12 months AZN insiders bought $3K of stock on the open market and sold $2.2M, according to SEC Form 4 filings.

AI Auto Pilots
Is AZN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold AZN.

Key Stats

Last 12 months
Results
Revenue
$58.7B
+8.6% vs a year ago
Net income
$10.2B
+45.3% vs a year ago
Free cash flow
$11.8B
20.0% margin
Gross margin
81.9%
$48.1B gross profit
Balance sheet
Cash & equivalents
$5.7B
At Dec 31
Debt
$29.6B
At Dec 31
Shareholder equity
$48.7B
CEOPascal Soriot
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2021: $37.4B$37.4BFY2021FY2022: $44.4B$44.4BFY2022FY2023: $45.8B$45.8BFY2023FY2024: $54.1B$54.1BFY2024FY2025: $58.7B$58.7BFY2025

From AZN's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Feb 24). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on file yet
Reported EPS
—
Quarter ended Jun 2025
Year ago EPS
—
Same quarter last year
Revenue
$14.46B
+11.7% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Not enough quarters on file yet.
Revenue by quarter
Sep 2020: $6.52BSep '20Dec 2020: $7.01BDec '20Mar 2021: $7.26BMar '21Jun 2021: $8.22BJun '21Jun 2022: $10.77BJun '22Jun 2023: $11.42BJun '23Jun 2024: $12.94BJun '24Jun 2025: $14.46BJun '25Latest $14.46B
StreetAlpha's call on AZNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on AZN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on AZN

Technical Analysis

AZN · as of the Nov 20 close · updated each morning
Moving sideways

The stock sits between its 20 and 50 day averages. It is 3% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 44). The nearest support is the swing low (Jun 18) at $173.66, and the nearest resistance the swing high (Jul 29) at $175.03.

Short trendNeutral
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 2.3%/day
Key levels
$212.7152 week high+22.0%
$181.5420 day average+4.1%
$179.99200 day average+3.2%
$176.53Pivot R1+1.3%
$175.29Pivot+0.5%
$175.03Swing high (Jul 29)+0.4%
$174.35Last close
$173.66Swing low (Jun 18)−0.4%
$173.10Pivot S1−0.7%
$170.7150 day average−2.1%
$168.75100 day average−3.2%
$153.4152 week low−12.0%
Indicators
RSI (14)44.20Middle of its rangeNeutral
MACD2.42Below its signal lineBearish
Stochastic4.1Near the bottom of its rangeOversold
ADX (14)21.5Weak trend
Williams %R-98.3Oversold below −80, overbought above −20Oversold
CCI (20)-77.6Oversold below −100, overbought above 100Neutral
Rate of change−6.5%Change over 10 sessionsBearish
ATR (14)$4.06Typical daily range, 2.3% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Below
What happened before, for AZN

What happened before

See how AZN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow AZN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How AZN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for AZNHow many large options trades hit AZN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

AZN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●681 buying vs 697 selling
  • ▼Shares held by funds -3.2%
  • ▼Funds holding -65
  • ▲Superinvestors: 5 added, 0 cut
  • ▲Put/call 4.27 to 0.43
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding1,4521,517−4.3%
In funds' top 104858−17.2%
Held by funds–––
New / increased138 / 543272 / 514−13.4%
Reduced / sold out513 / 184473 / 147+12.4%
Put/call ratio0.434.27−89.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AZN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AZN Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$3K1 buy · 1 insider
Sold$2.2M1 sale · 1 insider
2026-05 sold $2.2M2026-08 bought $3KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 8Mani SharmaSee RemarksBuy20$160.57$3K
May 20Mani SharmaSee RemarksSale11,893$185.78$2.2M
Every insider buy and sale for AZN over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See AZN insider trades →

From SEC Form 4 filings by AZN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AZN is in one of them and how their past AZN trades turned out.

AZN in the AI portfolios
Loading…

AZN News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AZN in an article yet. Here's the latest on the wider market.

AZN in the news

AZN Congress Trades

All congress trades →
Trades, 12 months
5
Buys
5
100%
Sells
0
0%
People
3
Last filed Jul 21
Who traded AZN · since 2014
Latest 5 filings of 42
$1K – $15KTraded Mar 31, 2026Filed Jul 21, 2026
$15K – $50KTraded Mar 30, 2026Filed Jul 21, 2026
$1K – $15KTraded Dec 8, 2025Filed Jan 13, 2026
$1K – $15KTraded Dec 18, 2025Filed Jan 12, 2026
$1K – $15KTraded Nov 19, 2025Filed Dec 15, 2025
PersonTypeAmountTradedFiledDelay
Alan ArmstrongR · OKBuy$1K – $15KMar 31, 2026Jul 21, 2026112 d
Alan ArmstrongR · OKBuy$15K – $50KMar 30, 2026Jul 21, 2026113 d
Julia LetlowR · LABuy$1K – $15KDec 8, 2025Jan 13, 202636 d
Gilbert CisnerosD · CABuy$1K – $15KDec 18, 2025Jan 12, 202625 d
Gilbert CisnerosD · CABuy$1K – $15KNov 19, 2025Dec 15, 202526 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Astrazeneca

AstraZeneca is a pharmaceutical company based in Cambridge that researches, develops and sells prescription medicines. Its work covers several therapy areas, including cancer, heart, kidney and metabolic disease, respiratory and immune conditions, rare diseases, and vaccines. Much of its research focuses on new treatments still in clinical trials, which it develops alone or with partners. Its medicines are aimed at patients and the healthcare providers who treat them.

Headquarters
Cambridge
Founded
1913